New frontiers in the treatment of liposarcoma, a therapeutically resistant malignant cohort

Drug Resistance Updates

Volumn 14, Issue 1, 2011, Pages 52-66

  Hoffman, Aviad ^a   Lazar, Alexander J ^a   Pollock, Raphael E ^a   Lev, Dina ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Dedifferentiation; Liposarcoma; MDM2; PI3K AKT; PPAR ; Targeted therapy; Trabectedin

Indexed keywords

2 (1H INDAZOL 4 YL) 6 (4 METHANESULFONYL 1 PIPERAZINYLMETHYL) 4 MORPHOLINOTHIENO[3,2 D]PYRIMIDINE; 6 ACETYL 8 CYCLOPENTYL 5 METHYL 2 [5 (1 PIPERAZINYL) 2 PYRIDINYLAMINO] 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; ANTINEOPLASTIC AGENT; AT 219; BROSTALLICIN; CC 401; CS 7017; DACARBAZINE; DEOXYRIBOZYME; DOXORUBICIN; EPIRUBICIN; FLAVOPIRIDOL; GEMCITABINE; IFOSFAMIDE; MK 2206; NUTLIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; RETASPIMYCIN; RIDAFOROLIMUS; RO 4929097; RO 5045337; SERDEMETAN; SUNITINIB; TEPROTUMUMAB; TRABECTEDIN; TROGLITAZONE; UNCLASSIFIED DRUG;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER SURGERY; CELL PROLIFERATION; DEDIFFERENTIATED LIPOSARCOMA; GENE AMPLIFICATION; GENE MUTATION; GENETIC REGULATION; HISTOLOGY; HUMAN; LIPOSARCOMA; MYXOSARCOMA; PLEOMORPHIC LIPOSARCOMA; PRIORITY JOURNAL; PROGNOSIS; ROUND CELL LIPOSARCOMA; SARCOMA; SOFT TISSUE TUMOR; SOLID TUMOR; TREATMENT OUTCOME; TREATMENT PLANNING; TUMOR DIFFERENTIATION; WELL DIFFERENTIATED LIPOSARCOMA;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL DEDIFFERENTIATION; CELL DIFFERENTIATION; DRUG DELIVERY SYSTEMS; DRUG DESIGN; DRUG RESISTANCE, NEOPLASM; HUMANS; LIPOSARCOMA; PROGNOSIS; TREATMENT OUTCOME;

EID: 79951958286     PISSN: 13687646     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drup.2010.11.001     Document Type: Article

References (220)

1. G. Adelmant, J.D. Gilbert, and S.O. Freytag Human translocation liposarcoma-CCAAT/enhancer binding protein (C/EBP) homologous protein (TLS-CHOP) oncoprotein prevents adipocyte differentiation by directly interfering w (Pubitemid 28298170)
2. P.B. Aleixo, A.A. Hartmann, I.C. Menezes, R.T. Meurer, and A.M. Oliveira Can MDM2 and CDK4 make the diagnosis of well differentiated/dedifferentiated liposarcoma? An immunohistochemical study on 129 soft tissue tumours J. Clin. Pathol. 62 2009 1127 1135
3. S. Altiok, D. Batt, N. Altiok, A. Papautsky, J. Downward, T.M. Roberts, and H. Avraham Heregulin induces phosphorylation of BRCA1 through phosphatidylinositol 3-Kinase/AKT in breast cancer cells J. Biol. Chem. 274 1999 32274 32278
4. P. Aman, D. Ron, N. Mandahl, T. Fioretos, S. Heim, K. Arheden, H. Willen, A. Rydholm, and F. Mitelman Rearrangement of the transcription factor gene CHOP in myxoid liposarcomas with t(12;16)(q13;p11) Genes Chromosomes Cancer 5 1992 278 285 (Pubitemid 23011197)
5. C.R. Antonescu, S.J. Tschernyavsky, R. Decuseara, D.H. Leung, J.M. Woodruff, M.F. Brennan, J.A. Bridge, J.R. Neff, J.R. Goldblum, and M. Ladanyi Prognostic impact of P53 status TLS-CHOP fusion transcript structure, and histological grade in myxoid liposarcoma: A molecular and clinicopathologic study of 82 cases Clin. Cancer Res. 7 2001 3977 3987 (Pubitemid 34044616)
6. C.R. Antonescu, A. Elahi, J.H. Healey, M.F. Brennan, M.Y. Lui, J. Lewis, S.C. Jhanwar, J.M. Woodruff, and M. Ladanyi Monoclonality of multifocal myxoid liposarcoma: confirmation by analysis of TLS-CHOP or EWS-CHOP rearrangements Clin. Cancer Res. 6 2000 2788 2793 (Pubitemid 30482118)
7. J. Barretina, B.S. Taylor, S. Banerji, A.H. Ramos, M. Lagos-Quintana, and P.L. Decarolis Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy Nat. Genet. 42 2010 715 721
8. M.V. Barone, A. Crozat, Tabaee, L. Philipson, and D. Ron CHOP (GADD153) and its oncogenic variant TLS-CHOP, have opposing effects on the induction of G1/S arrest Genes Dev. 8 1994 453 464 (Pubitemid 24071185)
9. A. Bellacosa, D. de Feo, A.K. Godwin, D.W. Bell, J.Q. Cheng, M. Wan, L. Dubeau, G. Scambia, V. Masciullo, G. Ferrandina, P. Benedetti Panici, S. Mancuso, G. Neri, and J.R. Testa Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas Int. J. Cancer 64 1995 280 285
10. A. Bertolotti, Y. Lutz, D.J. Heard, P. Chambon, and L. Tora hTAF(II)68, a novel RNA/ssDNA-binding protein with homology to the pro-oncoproteins TLS/FUS and EWS is associated with both TFIID and RNA polymerase II EMBO J. 15 1996 5022 5031 (Pubitemid 26315812)
11. W.H. Biggs 3rd, J. Meisenhelder, T. Hunter, W.K. Cavenee, and K.C. Arden Protein kinase B/Akt-mediated phosphorylation promotes nuclear exclusion of the winged helix transcription factor FKHR1 Proc. Natl. Acad. Sci. U. S. A. 96 1999 7421 7426 (Pubitemid 29299677)
12. S.L. Blair, J.J. Lewis, D. Leung, J. Woodruff, and M.F. Brennan Multifocal extremity sarcoma: an uncommon and controversial entity Ann. Surg. Oncol. 5 1998 37 40 (Pubitemid 28328056)
13. V. Bramwell, D. Anderson, and M. Charette Sarcoma Disease Site Group 2001. Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft tissue sarcoma Cochrane Database Syst. Rev. 4 2001 CD003293 10.1002/14651858 (Art. No.: CD003293)
14. M. Brennan Diagnosis and Management of Soft Tissue Sarcoma 2002 Martin Dunitz London
15. M. Broggini, S. Marchini, E. Fontana, D. Moneta, C. Fowst, and C. Geroni Brostallicin: a new concept in minor groove DNA binder development Anticancer Drugs 15 2004 1 6 (Pubitemid 39140165)
16. A. Brunet, A. Bonni, M.J. Zigmond, M.Z. Lin, P. Juo, L.S. Hu, M.J. Anderson, K.C. Arden, J. Blenis, and M.E. Greenberg Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor Cell 96 1999 857 868 (Pubitemid 29165088)
17. M.H. Cardone, N. Roy, H.R. Stennicke, G.S. Salvesen, T.F. Franke, E. Stanbridge, S. Frisch, and J.C. Reed Regulation of cell death protease caspase-9 by phosphorylation Science 282 1998 1318 1321 (Pubitemid 28524494)
18. A. Carnero High throughput screening in drug discovery Clin. Transl. Oncol. 8 2006 482 490
19. J.D. Carpten, A.L. Faber, C. Horn, G.P. Donoho, S.L. Briggs, and C.M. Robbins A transforming mutation in the pleckstrin homology domain of AKT1 in cancer Nature 448 2007 439 444 (Pubitemid 47123510)
20. T.H. Chang, and E. Szabo Induction of differentiation and apoptosis by ligands of peroxisome proliferator-activated receptor gamma in non-small cell lung cancer Cancer Res. 60 2000 1129 1138 (Pubitemid 30129556)
21. H.R. Chang, S.I. Hajdu, C. Collin, and M.F. Brennan The prognostic value of histologic subtypes in primary extremity liposarcoma Cancer 64 1989 1514 1520 (Pubitemid 19238971)
22. H. Cheng, J. Dodge, E. Mehl, S. Liu, N. Poulin, M. van de Rijn, and T.O. Nielsen Validation of immature adipogenic status and identification of prognostic biomarkers in myxoid liposarcoma using tissue microarrays Human Pathol. 40 2009 1244 1251
23. J.Q. Cheng, B. Ruggeri, W.M. Klein, G. Sonoda, D.A. Altomare, D.K. Watson, and J.R. Testa Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA Proc. Natl. Acad. Sci. U. S. A. 93 1996 3636 3641 (Pubitemid 26127592)
24. C.F. Cheok, C.S. Verma, J. Baselga, and D.P. Lane Translating p53 into the clinic Nat. Rev. Clin. Oncol. 2010 174 10.1038/nrclinonc.2010
25. F. Chibon, O. Mariani, J. Derré, S. Malinge, J.M. Coindre, L. Guillou, R. Lagacé, and A. Aurias A subgroup of malignant fibrous histiocytomas in associated with genetic changes similar to those of well-differentiated liposarcomas Cancer Genet. Cytogenet. 139 2002 24 29 (Pubitemid 36120402)
26. F. Chibon, O. Mariani, J. Derre, A. Mairal, J.M. Coindre, L. Guillou, X. Sastre, F. Pedeutour, and A. Aurias ASK1 (MAP3K5) as a potential therapeutic target in malignant fibrous histiocytomas with 12q14-q15 and 6q23 amplifications Genes Chromosomes Cancer 40 2004 32 37 (Pubitemid 38524616)
27. G. Choe, S. Horvath, T.F. Cloughesy, K. Crosby, D. Seligson, A. Palotie, L. Inge, B.L. Smith, C.L. Sawyers, and C.L. Mischel Analysis of the phosphatidylinositol 3′-kinase signaling pathway in glioblastoma patients in vivo Cancer Res. 63 2003 2742 2746 (Pubitemid 36667143)
28. P.J. Coffer, J. Jin, and J.R. Woodgett Protein kinase B (c-Akt): a multifunctional mediator of phosphatidylinositol 3-kinase activation Biochem. J. 335 1998 1 13 (Pubitemid 28477043)
29. K.S. Cook, D.L. Groves, H. Min, and B.M. Spiegelman A developmentally regulated mRNA from 3T3 adipocytes encodes a novel serine proteasehomologue Proc. Natl. Acad. Sci. U. S. A. 82 1985 6480 6484 (Pubitemid 16230537)
30. K.D. Courtney, B. Ryan, R.B. Corcoran, and J.A. Engelman The P13K pathway as drug target in human cancer J. Clin. Oncol. 28 2010 1075 1083
31. M.S. Cragg, J. Kuroda, H. Puthalakath, D.C. Huang, and A. Strasser Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics PloS Med. 4 2007 1681 1689
32. A. Crozat, P. Aman, N. Mandahl, and D. Ron Fusion of CHOP to a novel RNA-binding protein in human myxoid liposarcoma Nature 363 1993 640 644 (Pubitemid 23227627)
33. K.M. Dalal, C.R. Antonescu, and S. Singer Diagnosis and management of lipomatous J. Surg. Oncol. 97 2008 298 313
34. C.R. Dass, S.J. Galloway, J.C. Clark, L.M. Khachigian, and P.F. Choong Involvement of c-jun in human liposarcoma growth: supporting data from clinical immunohistochemistry and DNAzyme efficacy Cancer Biol. Ther. 7 2008 1297 1301
35. S.R. Datta, A. Brunet, and M.E. Greenberg Cellular survival: a play in three Akts Genes Dev. 13 1999 2905 2927
36. G. Debrock, V. Vanhentenrijk, R. Sciot, M. Debiec-Rychter, R. Oyen, and A. Van Oosterom A phase II trial with rosiglitazone in liposarcoma patients Br. J. Cancer 89 2003 1409 1412 (Pubitemid 37386592)
37. A.P. Dei Tos, and F. Pedeutour A typical lipomatous tumour/well differentiated liposarcoma C.D.M. Fletcher, K.K. Unni, F. Mertens, Pathology and Genetics. Tumours of soft tissue and bone 2002 IARC Lyon 35 37
38. T.F. DeLaney, A.V. Trofimov, M. Engelsman, and H.D. Suit Advanced technology radiation therapy in the management of bone and soft tissue sarcomas Cancer Control 12 2005 27 35
39. G.D. Demetri Soft tissue sarcoma J. Natl. Compr. Canc. Netw. 5 2007 364 399
40. G.D. Demetri, A.T. van Oosterom, C.R. Garrett, M.E. Blackstein, M.H. Shah, J. Verweij, G. McArthur, I.R. Judson, M.C. Heinrich, J.A. Morgan, J. Desai, C.D. Fletcher, S. George, C.L. Bellow, X. Huang, C.M. Baum, and P.G. Casali Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial Lancet 368 2006 1329 1338 (Pubitemid 44528723)
41. G.D. Demetri, C.D. Fletcher, E. Mueller, P. Sarraf, R. Naujoks, N. Campbell, B.M. Spiegelman, and S. Singer Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma Proc. Natl. Acad. Sci. U. S. A. 96 1999 3951 3956 (Pubitemid 29169017)
42. M.A. Dickson, D.E. Rathkopf, R.D. Carvajal, S. Grant, J.D. Roberts, J.M. Reid, M.M. Ames, R.M. McGovern, R.A. Lefkowitz, M. Gonen, L.M. Cane, H.J. Dials, and G.K. Schwartz A phase I pharmacokinetic study of pulse-dose vorinostat with flavopiridol in solid tumors Invest. New Drugs 2010 10.1007/s10637-010-9447-x
43. K.A. Downes, J.R. Goldblum, E.A. Montgomery, and C. Fisher Pleomorphic liposarcoma: a clinicopathologic analysis of 19 cases Mod. Pathol. 14 2001 179 184 (Pubitemid 32246821)
44. J.H. Edmonson, L.P. Ebbert, A.G. Nascimento, S.H. Jung, H. McGaw, and J.B. Gerstner Phase II study of docetaxel in advanced soft tissue sarcomas Am. J. Clin. Oncol. 19 1996 574 576 (Pubitemid 26384705)
45. D. Engelmann, and B.M. Pützer Translating DNA damage into cancer cell death-A roadmap for E2F1 apoptotic signalling and opportunities for new drug drug combinations to overcome chemoresistance Drug Resist. Updat. 13 2010 119 131
46. E. Erba, D. Bergamaschi, L. Bassano, G. Damia, S. Ronzoni, G.T. Faircloth, and M. D'Incalci Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action Eur. J. Cancer. 37 2001 97 105 (Pubitemid 32119366)
47. H.L. Evans, E.H. Soule, and R.K. Winkelmann A typical lipoma, atypical intramuscular lipoma, and well differentiated retroperitoneal liposarcoma: a reappraisal of 30 cases formerly classified as well differentiated liposarcoma Cancer 43 1979 574 584 (Pubitemid 9122282)
48. E. Fabre-Guillevin, R. Tabrizi, V. Coulon, A. Monnereau, H. Eghbali, I. Soubeyran, and P. Soubeyran Retroperitoneal liposarcomas: follow-up analysis of dedifferentiation after clinicopathologic reexamination of 86 liposarcomas and malignant fibrous histiocytomas Cancer 106 2006 2725 2733
49. J. Fayette, N. Penel, C. Chevreau, J.Y. Blay, D. Cupissol, A. Thyss, C. Guillemet, M. Rios, F. Rolland, P. Fargeot, J.O. Bay, S. Mathoulin-Pelissier, J.M. Coindre, and B. Bui-Nguyen Phase III trial of standard versus dose-intensified doxorubicin, ifosfamide and dacarbazine (MAID) in the first-line treatment of metastatic and locally advanced soft tissue sarcoma Invest. New Drugs 27 2009 482 489
50. U. Fischer, D. Heckel, A. Michel, M. Janka, T. Hulsebos, and E. Meese Cloning of a novel transcription factor-like gene amplified in human glioma including astrocytoma grade I Hum. Mol. Genet. 6 1997 1817 1822 (Pubitemid 27460355)
51. C.D.M. Fletcher, Pathology and Genetics of Soft Tissue and Bone: World Health Organization Classification of Tumors 2002 IARC Press Lyon, France
52. C.D. Fletcher Will we ever reliably predict prognosis in a patient with myxoid and round cell liposarcoma? Adv Anat. Pathol. 4 1997 108 113
53. C.D. Fletcher Pleomorphic malignant fibrous histiocytoma: fact or fiction? A critical reappraisal based on 159 tumors diagnosed as pleomorphic sarcoma Am. J. Surg. Pathol. 16 1992 213 228
54. C. Forni, M. Minuzzo, e. Virdis, E. Tamborini, M. Simone, M. Tavecchio, E. Erba, F. Grosso, A. Gronchi, P. Aman, P. Casali, M. D'Incalci, S. Pilotti, and R. Mantovani Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors Mol. Cancer Ther. 8 2009 449 457
55. A. Forus, V.A. Florenes, G.M. Maeloandsmo, P.S. Meltzer, O. Fodstad, and O. Myklebost Mapping of amplification units in the q13-14 region of chromosome 12 in human sarcomas: Some amplica do not include MDM2 Cell Growth Differ. 4 1993 1065 1070 (Pubitemid 2020828)
56. T.F. Franke, D.R. Kaplan, L.C. Cantley, and A. Toker Direct regulation of the Akt protooncogene product by phosphatidylinositol-3,4-bisphosphate Science 275 1997 665 668 (Pubitemid 27061333)
57. S. Frustaci, A. De Paoli, E. Bidoli, N. La Mura, M. Berretta, A. Buonadonna, G. Boz, and F. Gherlinzoni Ifosfamide in the adjuvant therapy of soft tissue sarcomas Oncology 65 2003 80 84 (Pubitemid 37346738)
58. S. Frustaci, F. Gherlinzoni, A. De Paoli, M. Bonetti, A. Azzarelli, A. comandone, P. Olmi, A. Buonadonna, G. Pignatti, E. Barbieri, G. Apice, H. Zmerly, D. Serraino, and P. Picci Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial J. Clin. Oncol. 19 2001 1238 1247 (Pubitemid 32202526)
59. I. Galetic, M. Andjelkovic, R. Meier, D. Brodbeck, J. Park, and B.A. Hemmings Mechanism of protein kinase B activation by insulin/insulin-like growth factor-1 revealed by specific inhibitors of phosphoinositide 3-kinase - significance for diabetes and cancer Pharmacol. Ther. 82 1999 409 425 (Pubitemid 29255934)
60. R. Garcia-Carbonero, J.G. Supko, J. Manola, M.V. seiden, D. Harmon, d.P. Ryan, M.T. Quigley, P. Merriam, J. Canniff, G. Goss, U. Matulonis, R.G. Maki, t. Lopez, T.A. Puchalski, M.A. Sancho, J. Gomez, C. Guzman, J. Jimeno, and G.D. Demerti Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy J. Clin. Oncol. 22 2004 1480 1490 (Pubitemid 41103631)
61. S. Gebhard, J.M. Coindre, J.J. Michels, P. Terrier, G. Bertrand, M. Trassard, S. Taylor, M.D. Chateau, B. Marques, V. Picot, and L. Guillou Pleomorphic liposarcoma: clinicopathologic, immunohistochemical, and followup analysis of 63 cases. A study from the French Federation of Cancer Centers Sarcoma Group Am. J. Surg. Pathol. 26 2002 601 616 (Pubitemid 34438720)
62. Gelderblom, H., Blay, J.Y., Seddon, B. M., Leahy, M., Ray-Coquard, I.L., De Brauwer, A., Veyt, E., Weitman, S.D., Hogendoorn, P.C.W., Hohenberger, P., 2010. An EORTC Soft Tissue and Bone Sarcoma Group randomized phase II study. ASCO Annual Meeting (Abstract).
63. G. Germano, R. Frapolli, M. Simone, M. Tavecchio, E. Erba, S. Pesce, F. Pasqualini, F. Grosso, R. Sanfilippo, P.G. Casali, A. Gronchi, E. Virdis, E. Tarantino, S. Pilotti, A. Greco, M. Nebuloni, C.M. Galmarini, J.C. Tercero, A. Mantovani, M. D'Incalci, and P. Allavena Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells Cancer Res. 70 2010 2235 2244
64. H.L. Gieschen, I.J. Spiro, H.D. Suit, M.J. Ott, D.W. Rattner, M. Ancukiewicz, and C.G. Willett Long-term results of intraoperative electron beam radiotherapy for primary and recurrent retroperitoneal soft tissue sarcoma Int. J. Radiat. Oncol. Biol. Phys. 50 2001 127 131
65. M.K. Göransson, C. Andersson, A. Forni, C. Stahlberg, A. Andersson, A. Olofsson, R. Mantovani, and P. Aman The myxoid liposarcoma FUS-DDIT3 fusion oncoprotein deregulates NF-kB target genes by interaction with NFKBIZ M Oncogene 28 2009 270 278
66. E. Gortzak, A. Azzarelli, J. Buesa, V.H. Bramwell, F. van Coevorden, A.N. van Geel, A. Ezzat, A. Santoro, J.W. Oosterhuis, M. van Glabbeke, A. Kirkpatrick, and J.A. Verweij Randomised phase II study on neo-adjuvant chemotherapy for 'high-risk' adult soft-tissue sarcoma.E.O.R.T.C. Soft Tissue Bone Sarcoma Group and the National Cancer Institute of Canada Clinical Trials Group/Canadian Sarcoma Group Eur. J. Cancer 37 2001 1096 1103
67. A. Gronchi, P.G. Casali, M. Fiore, L. Mariani, S. Lo Vullo, R. bertulli, M. Colecchia, L. Lozza, P. Olmi, M. Santinami, and J. Rosai Retroperitoneal soft tissue sarcomas: patterns of recurrence in 167 patients treated at a single institution Cancer 100 2004 2448 2455 (Pubitemid 38657895)
68. F. Grosso, R.L. Jones, G.D. Demetri, I.R. Judson, J.Y. Blay, and A. Le Cesne Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study Lancet Oncol. 8 2007 595 602 (Pubitemid 46995623)
69. F. Grosso, R. Sanfilippo, E. Virdis, C. Piovesan, P. Collini, P. Dileo, C. Morosi, J.C. Tercero, J. Jimeno, M. D'Incalci, A. Gronchi, S. Pilotti, and P.G. Casali Trabectedin in myxoid liposarcomas (MLS): a long-term analysis of a single-institution series Ann. Oncol. 20 2009 1439 1444
70. L. Gu, N. Zhu, H.W. Findley, and M. Zhou MDM2 antagonist nutlin-3 is a potent inducer of apoptosis in pediatric acute lymphoblastic leukemia cells with wild-type p53 and overexpression of MDM2 Leukemia 22 2008 730 739 (Pubitemid 351552622)
71. B.A. Guadagnolo, G.K. Zagars, M.T. Ballo, S.R. Patel, V.O. Lewis, R.S. Benjamin, and R.E. Pollock Excellent local control rates and distinctive patterns of failure in myxoid liposarcoma treated with conservation surgery and radiotherapy Int. J. Radiat. Oncol. Biol. Phys. 70 2008 760 765 (Pubitemid 351199710)
72. M. Guarino, B. Rubino, and G. Ballabio The role of epithelial to mesenchymal transition in cancer pathology Pathology 39 2007 305 318 (Pubitemid 46897605)
73. J.A. Hannay, J. Liu, Q.S. Zhu, S.V. Bolshakov, L. Li, P.W. Pisters, A.J. Lazar, D. Yu, R.E. Pollock, and D. Lev Rad51 overexpression contributes to chemoresistance in human soft tissue sarcoma cells: a role for p53/activator protein 2 transcriptional regulation Mol Cancer Ther. 6 2007 1650 1660 (Pubitemid 46954032)
74. Y. Haupt, R. Maya, A. Kazaz, and M. Oren Mdm2 promotes the rapid degradation of p53 Nature 387 1997 296 299 (Pubitemid 27220766)
75. W.H. Henricks, Y.C. Chu, J.R. Goldblum, and S.W. Weiss Dedifferentiated liposarcoma. A clinicopathologic analysis of 155 cases with a proposal for an expanded definition of dedifferentiation Am. J. Surg. Pathol. 21 1997 271 281 (Pubitemid 27120195)
76. E. Hernando, E. Charytonowicz, M.E. Dudas, S. Menendez, I. Matushansky, J. Mills, M.D. Socci, N. Behrendt, L. Ma, R.G. Maki, P.P. Pandolfi, and C. Cordon-Cardo The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas Nat. Med. 13 2007 748 753 (Pubitemid 46889749)
77. R. Honda, H. Tanaka, and H. Yasuda Oncoprotein MDM2 is a ubiquitin ligase E3 for tumore supperessor p53 FEBS Lett. 420 1997 25 27 (Pubitemid 28037193)
78. A. Horiguchi, M. Oya, A. Uchida, K. Marumo, and M. Murai Elevated Akt activation and its impact on clinicopathological features of renal cell carcinoma J. Urol. 169 2003 710 713 (Pubitemid 36133028)
79. J.L. Hornick, M.W. Bosenberg, T. Mentzel, M.E. McMenamin, A.M. Olivira, and C.D. Fletcher Pleomorphic liposarcoma. Clinicopathologic analysis of 57 cases Am. J. Surg. Pathol. 28 2004 1257 1267 (Pubitemid 39336365)
80. I. Hostein, M. Pelmus, A. Aurias, F. Pedeutour, S. Mathoulin-Pelissier, and J.M. Coindre Evaluation of MDM2 and CDK4 amplification by real-time PCR on paraffin wax-embedded material: a potential tool for the diagnosis of atypical lipomatous tumours/well-differentiated liposarcomas J. Pathol. 202 2004 95 102 (Pubitemid 38072850)
81. C.H. Huang, D. Mandelker, O. Schmidt-Kittler, Y. Samuels, V.E. Velculescu, K.W. Kinzler, B. Vogelstein, S.B. Gabelli, and L.M. Amzel The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations Science 318 2007 1744 1748 (Pubitemid 350274378)
82. A. Italiano, L. Bianchini, F. Keslair, S. Bonnafous, N. Cardot-Leccia, J.M. Coindre, J.M. Dumollard, P. Hofman, A. Leroux, C. Mainguené, I. Peyrottes, D. Ranchere-Vince, P. Terrier, A. Tran, P. Gual, and F. Pedeutour HMGA2 is the partner of MDM2 in well-differentiated and dedifferentiated liposarcomas whereas CDK4 belongs to a distinct inconsistent amplicon Int. J. Cancer. 122 2008 2233 2241 (Pubitemid 351542325)
83. N. Jaffe, E. Frei, D. Traggis, and H. Watts Weekly high-dose methotrexate-citrovorum factor in osteogenic sarcoma: pre-surgical treatment of primary tumor and of overt pulmonary metastases Cancer 39 1977 45 50 (Pubitemid 8028976)
84. A. Jemal, R. Siegel, J. Xu, and E. Ward Cancer statistics CA Cancer J. Clin. 60 2010 277 300
85. D. Jaques, D.G. Coit, S. Hajdu, and M.F. Brennan Management of primary and recurrent soft tissue sarcoma of the retroperitoneum Ann Surg. 212 1990 51 59 (Pubitemid 20215915)
86. H. Joensuu, P.J. Roberts, M. Sarlomo-Rikala, L.C. Andersson, P. Tervahartiala, D. Tuveson, S. Silberman, R. Capdeville, S. Dimitrijevic, B. Druker, and G.D. Demetri Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor New Engl. J. Med. 344 2001 1052 1056 (Pubitemid 32267975)
87. B.E. Johnson, and P.A. Jänne Rationale for a phase II trial of pertuzumab, a HER-2 dimerization inhibitor, in patients with non-small cell lung cancer Clin. Cancer Res. 12 2006 4436s 4440s (Pubitemid 44197195)
88. K.A. Johnson, and P.H. Brown Drug development for cancer chemoprevention: focus on molecular targets Semin. Oncol. 37 2010 345 358
89. J.J. Jones, C.N. Catton, B. O'Sullivan, J. Couture, R.L. Heisler, R.A. Kandel, and C.J. Swallow Initial results of a trial of preoperative external-beam radiation therapy and postoperative brachytherapy for retroperitoneal sarcoma Ann. Surg. Oncol. 9 2002 346 354 (Pubitemid 34496722)
90. K. Kalluri, and R.A. Weinberg The basics of epithelia-mesenchymal transition J. Clin. Invest. 119 2009 1420 1428
91. Y. Kanamori, J. Kigawa, H. Itamochi, M. Shimada, M. Takahashi, S. Kamazawa, S. Sato, R. Akeshima, and N. Terakawa Correlation between loss of PTEN expression and Akt phosphorylation in endometrial carcinoma Clin Cancer Res. 7 2001 892 895 (Pubitemid 32708726)
92. E.S. Kandel, and N. Hay The regulation and activities of the multifunctional serine/threonine kinase Akt/PKB Exp. Cell Res. 253 1999 210 229
93. Y. Kaneko, H. Kobayashi, M. Handa, N. Satake, and N. Maseki EWS-ERG fusion transcript produced by chromosomal insertion in a Ewing sarcoma Genes Chromosomes Cancer 18 1997 228 231 (Pubitemid 27120342)
94. Y. Kato, H. Ying, L. Zhao, F. Furuya, O. Araki, M.C. Willingham, and S.Y. Cheng PPARgamma insufficiency promotes follicular thyroid carcinogenesis via activation of the nuclear factor-kappaB signaling pathway Oncogene 25 2006 2736 2747
95. M.V. Kisseleva, L. Cao, and P.W. Majerus Phosphoinositide-specific inositol polyphosphate 5-phosphatase IV inhibits Akt/protein kinase B phosphorylation and leads to apoptotic cell death J. Biol. Chem. 277 2002 6266 6272 (Pubitemid 34968418)
96. M. Kitagawa, M. Aonuma, S.H. Lee, S. Fukutake, and F. McCormick E2F-1 transcriptional activity is a critical determinant of Mdm2 antagonist-induced apoptosis in human tumor cell lines Oncogene 27 2008 5303 5314
97. J.C. Knight, P.J. Renwick, P. Dal Clin, H. Van den Berghe, and C.D. Fletcher Translocation t(12;16)(q13;p11) in myxoid liposarcoma and round cell liposarcoma: molecular and cytogenetic analysis Cancer Res. 55 1995 24 27
98. W.J. Köstler, T. Brodowicz, Y. Attems, M. Hejna, S. Tomek, g. Amann, W.C. Fiebiger, C.H. Wiltschke, M. Krainer, and C.C. Zielinski Docetaxel as rescue medication in anthracyclineand ifosfamide-resistant locally advanced or metastatic soft tissue sarcoma: Results of a phase II trial Ann. Oncol. 12 2001 1281 1288 (Pubitemid 32994758)
99. W.G. Kraybill, J. Harris, I.J. Spiro, D.S. Ettinger, T.F. DeLaney, R.H. Blum, D.R. Lucas, D.C. Harmon, G.D. Letson, and B. Eisenberg Long-term results of a phase 2 study of neoadjuvant chemotherapy and radiotherapy in the management of high-risk, high-grade, soft tissue sarcomas of the extremities and body wall: Radiation Therapy Oncology Group Trial 9514 Cancer 116 2010 4613 4621
100. J.I. Kreisberg, S.N. Malik, T.J. Prihoda, R.G. Bedolla, D.A. Troyer, S. Kreisberg, and P.M. Ghosh Phosphorylation of Akt (Ser473) is an excellent predictor of poor clinical outcome in prostate cancer Cancer Res. 64 2004 5232 5236 (Pubitemid 39006542)
101. K. Kurose, X.P. Zhou, T. Araki, S.A. Cannistra, E.R. Maher, and C. Eng Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels, but not associated with p27 and cyclin D1 expression, in primary epithelial ovarian carcinomas Am. J. Pathol. 158 2001 2097 2106 (Pubitemid 32545195)
102. T.J. Kwiatkowski Jr., D.A. Bosco, A.L. LeClerc, E. Tamrazian, C.R. Vanderburg, and C. Russ Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis Science 323 2009 1205 1208
103. G. Lahat, D.A. Anaya, X. Wang, D. Tuvin, D. Lev, and R.E. Pollock Resectable well-differentiated versus dedifferentiated liposarcomas: two different diseases possibly requiring different treatment approaches Ann. Surg. Oncol. 15 2008 1585 1593
104. C. Lanckohr, A. Kasprzynski, L. Klein-Hitpass, H.H. Homann, M. Lehnhardt, O. Müller, C. Kuhnen, and P. Herter Identification of genes over-expressed in myxoid/round cell liposarcomaDNA microarray analysis and immunohistochemical correlation Pathologe 31 2010 60 66
105. N.A. Laurie, S.L. Donovan, C.S. Shih, J. Zhang, N. Mills, and C. Fuller Inactivation of the p53 pathway in retinoblastoma Nature 444 2006 61 66 (Pubitemid 44684754)
106. M. Leahy, I. Ray-Coquard, J. Verweij, A. Le Cesne, F. Duffaud, P.C. Hogendoorn, C. Fowst, C. de Balincourt, E.D. di Paola, M. van Glabbeke, I. Judson, and J.Y. Blay Brostallicin, an agent with potential activity in metastatic soft tissue sarcoma: A phase II study from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Eur. J. Cancer 43 2007 308 315 (Pubitemid 46138040)
107. Y.M. Lee, and P. Sicinski Targeting cyclins and cyclin-dependent kinases in cancer: lessons from mice, hopes for therapeutic applications in human Cell Cycle 5 2006 2110 2114 (Pubitemid 44553745)
108. J.M. Lehmann, L.B. Moore, T.A. Smith-Oliver, W.O. Wilkison, T.M. Willson, and S.A. Kliewer An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma) J. Biol. Chem. 270 1995 12953 12956
109. M.A. Lemmon, and J. Schlessinger Cell signaling by receptor tyrosine kinases Cell 141 2010 1117 1134
110. S. Llanos, A. Efeyan, J. Monsech, O. Dominguez, and M. Serrano Highthroughput loss-of-function screening identifies novel p53 regulators Cell Cycle 5 2006 1880 1885 (Pubitemid 44435334)
111. J. LoPiccolo, G.M. Blumenthal, W.B. Bernstein, and P.A. Dennis Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations Drug Resist Updat. 11 2008 32 50
112. T.V. Maerken, F. Speleman, J. Vermeulen, I. Lambertz, S. De Clercq, E. De Smet, N. Yigit, V. Coppens, J. Philippe, A. De Paepe, J.C. Marine, and J. Vandesompele Small-molecule MDM2 antagonists as a new therapy concept for neuroblastoma Cancer Res. 66 2006 9646 9655 (Pubitemid 44623664)
113. B.D. Manning, and L.C. Cantley AKT/PKB signaling: navigating downstream Cell 129 2007 1261 1274 (Pubitemid 46962095)
114. R.G. Maki, J.K. Wathen, S.R. Patel, D.A. Priebat, S.H. Okuno, B. Samuels, M. Fanucchi, D.C. Harmon, S.M. Schuetze, D. Reinke, P.F. Thall, R.S. Benjamin, L.H. Baker, and M.L. Hensley Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 J. Clin. Oncol. 25 2007 2755 27863
115. R.G. Maki, M.L. Keohan, and S.D. Undevia Updated results of a phase II study of oral multi-kinase inhibitor sorafenib in sarcomas CTEP study #7060 J. Clin. Oncol. 26 2008 105 131
116. M. Malumbres, and M. Barbacid Cell cycle. CDKs and cancer: a changing paradigm Nat. Rev. Cancer 9 2009 153 166
117. O. Mariani, C. Brennetot, J.M. Coindre, N. Gruel, C. Ganem, O. Delattre, M.H. Stern, and A. Aurias JUN oncogene amplification and overexpression block adipocytic differentiation in highly aggressive sarcomas Cancer Cell 11 2007 361 374 (Pubitemid 46518313)
118. J.M. Meis "Dedifferentiation" in bone and soft-tissue tumors. A histological indicator of tumor progression Pathol. Ann. 26 1991 37 62
119. T. Mentzel, and C.D. Fletcher Lipomatous tumours of soft tissues: An update Virchows Arch. 427 1995 353 363 (Pubitemid 26009607)
120. O. Merimsky, I. Meller, Y. Kollender, J. Issakov, G. Flusser, and M. Inbar Gemcitabine in soft tissue or bone sarcoma resistant to standard chemotherapy: A phase II study Cancer Chemother. Pharmacol. 45 2000 177 181 (Pubitemid 30090250)
121. N. Miled, Y. Yan, W.C. Hon, O. Perisic, M. Zvelebil, Y. Inbar, D. Schneidman-Duhovny, H.J. Wolfson, J.M. Backer, and R.L. Williams Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit Science 13 2007 239 242 (Pubitemid 47076198)
122. M. Minuzzo, S. Marchini, M. Broggini, G. Faircloth, M. D'Incalci, and R. Mantovani Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743 Proc. Natl. Acad. Sci. U.S.A. 97 2000 6780 6784 (Pubitemid 30412791)
123. M. Miyachi, N. Kakazu, S. Yagyu, Y. Katsumi, S. Tsubai-Shimizu, K. Kikuchi, K. Tsuchiya, T. Iehara, and H. Hosoi Restoration of p53 pathway by nutlin-3 induces cell cycle arrest and apoptosis in human rhabdomyosarcoma cells Clin. Cancer Res. 15 2009 4077 4084
124. T.F. Molinski, D.S. Dalisay, S.L. Lievens, and J.P. Saludes Drug development from marine natural products Nat. Rev. Drug Discov. 8 2009 69 85
125. J. Momand, H.H. Wu, and G. Dasgupta MDM2-master regulator of the p53 tumor suppressor protein Gene 242 2000 15 29 (Pubitemid 30064488)
126. J. Momand, G.P. Zambetti, D.C. Olson, D. George, and A.J. Levine The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation Cell 69 1992 1237 1245
127. M. Montagnani, H. Chen, V.A. Barr, and M.J. Quon Insulin-stimulated activation of eNOS is independent of Ca2+ but requires phosphorylation by Akt at Ser(1179) J. Biol. Chem. 276 2001 30392 30398
128. S. Morgan-Lappe, K.W. Woods, Q. Li, M.G. Anderson, M.E. Schurdak, Y. Luo, V.L. Giranda, S.W. Fesik, and J.D. Leverson RNAi-based screening of the human kinome identifies Akt-cooperating kinases: a new approach to designing efficacious multitargeted kinase inhibitors Oncogene 25 2006 1340 1348 (Pubitemid 43336462)
129. E. Mueller, P. Sarraf, P. Tontonoz, R.M. Evans, K.J. Martin, M. Zhang, C. Fletcher, S. Singer, and B.M. Spiegelman Terminal differentiation of human breast cancer through PPAR gamma Mol. Cell 1 1998 465 470 (Pubitemid 128378895)
130. C.R. Müller, E.B. Paulsen, P. Noordhuis, F. Pedeutour, G. Saeter, and O. Myklebost Potential for treatment of liposarcomas with the MDM2 antagonist Nutlin-3A Int. J. Cancer 121 2007 199 205 (Pubitemid 46753868)
131. A. Munnia, N. Schütz, B.F. Romeike, E. Maldener, B. Glass, R. Maas, W. Nastainczyk, W. Feiden, U. Fischer, and E. Meese Expression, cellular distribution and protein binding of the glioma amplified sequence (GAS41), a highly conserved putative transcription factor Oncogene 20 2001 4853 4863 (Pubitemid 32803155)
132. Y. Nakamura, T. Suzuki, A. Sugawara, Y. Arai, and H. Sasano Peroxisome proliferator-activated receptor gamma in human prostate carcinoma Pathol. Int. 59 2009 288 293
133. H. Nakayama, T. Ikebe, M. Beppu, and K. Shirasuna High expression levels of nuclear factor kappaB. IkappaB kinase alpha and Akt kinase in squamous cell carcinoma of the oral cavity Cancer 92 2001 3037 3044 (Pubitemid 33136198)
134. S.Y. Nam, H.S. Lee, G.A. Jung, J. Choi, S.J. Cho, M.K. Kim, W.H. Kim, and B.L. Lee Akt/PKB activation in gastric carcinomas correlates with clinicopathologic variables and prognosis Apmis 111 2003 1105 1113 (Pubitemid 38091249)
135. R. Nahta, G.N. Hortobagyi, and F.J. Esteva Growth factor receptors in breast cancer: potential for therapeutic intervention Oncologist 8 2003 5 17 (Pubitemid 36232352)
136. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology, "Soft Tissue Sarcoma. Version 2.2008," National Comprehensive Cancer Network, Inc., May 2008.
137. S.J. Neuhaus, P. Barry, M.A. Clark, A.J. Hayes, C. Fisher, and J.M. Thomas Surgical management of primary and recurrent retroperitoneal liposarcoma Br. J. Surg. 92 2005 246 252 (Pubitemid 40269344)
138. Y. Ofir-Rosenfeld, K. Boggs, D. Michael, M.B. Kastan, and M. Oren Mdm2 regulates p53 mRNA translation through inhibitory interactions with ribosomal protein L26 Mol. Cell 32 2008 180 189
139. A. Okuno, H. Tamemoto, K. Tobe, K. Ueki, Y. Mori, K. Iwamoto, K. Umesono, Y. Akanuma, T. Fujiwara, H. Horikoshi, Y. Yazaki, and T. Kadowaki Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats J. Clin. Invest. 101 1998 1354 1361 (Pubitemid 28145252)
140. S. Okuno, L.M. Ryan, J.H. Edmonson, D.A. Priebat, and R.H. Blum Phase II trial of gemcitabine in patients with advanced sarcomas (E1797): A trial of the Eastern Cooperative Oncology Group Cancer 97 2003 1969 1973 (Pubitemid 36397273)
141. A.M. Oliveira, and A.G. Nascimento Pleomorphic liposarcoma Semin. Diagn. Pathol. 18 2001 274 285 (Pubitemid 33089755)
142. A. Olofsson, H. Willén, M. Göransson, K. Engström, J.M. Meis-Kindblom, G. Stenman, L.G. Kindblom, and P. Aman Abnormal expression of cell cycle regulators in FUS-CHOP carrying liposarcomas Int. J. Oncol. 25 2004 1349 1355
143. S. Ortega, M. Malumbres, and M. Barbacid Cyclin D-dependent kinases, INK4 inhibitors and cancer Biochim. Biophys. Acta 1602 2002 73 87 (Pubitemid 34311901)
144. B. O'Sullivan, A.M. Davis, R. Turcotte, R. Bell, C. Catton, P. Chabot, J. Wunder, R. Kandel, K. Goddard, A. Sadura, J. Pater, and B. Zee Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial Lancet 359 2002 2235 2241 (Pubitemid 34717977)
145. I. Panagopoulos, P. man, N. Mandahl, and F. Mitelman Two distinct FUS breakpoint clusters in myxoid liposarcoma and acute myeloid leukemia with the translocations t(12;16) and t(16;21) Oncogene 11 1995 1133 1137
146. J.H. Park, and R.G. Roeder GAS41 is required for repression of the p53 tumor suppressor pathway during normal cellular proliferation Mol. Cell. Biol. 26 2006 4006 4016 (Pubitemid 43788005)
147. S.R. Patel, V. Gandhi, J. Jenkins, N. Papadopolous, M.A. burger, C. Plager, W. Plunkett, and R.S. Benjamin Phase II clinical investigation of gemcitabine in advanced softtissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation J. Clin. Oncol. 19 2001 3483 3489 (Pubitemid 32730085)
148. F. Pedeutour, R.F. Suijkerbuijk, A. Forus, J. Van Gaal, W. Van de Klundert, J.M. Coindre, G. Nicolo, F. Collin, U. Van Haelst, and K. Huffermann Complex composition and co-amplification of SAS and MDM2 in ring and giant rod marker chromosomes in well-differentiated liposarcomas Genes Chromosomes Cancer 10 1994 85 94 (Pubitemid 24155978)
149. F. Pedeutour, A. Forus, J.M. Coindre, J.M. Berner, G. Nicolo, J.F. Michiels, P. Terrier, D. Ranchere-Vince, F. Collin, O. Myklebost, and C. Turc-Carel Structure of the supernumerary ring and giant rod chromosomes in adipose tissue tumors Genes Chromosomes Cancer 24 1999 30 41 (Pubitemid 28544460)
150. T. Peng, P. Zhang, J. Liu, T. Nguyen, S. Bolshakov, R. Belousov, E.D. Young, X. Wang, K. Brewer, D. Lopez-Terrada, A.M. Oliveira, A.J. Lazar, and D. Lev An experimental model for the study of well differentiated and dedifferentiated liposarcoma; deregulation of targetable tyrosine kinase receptors Lab. Invest. 2011 185 10.1038/labinvest.2010.185
151. I. Pérez de Castro, G. de Cárcer, G. Montoya, and M. Malumbres Emerging cancer therapeutic opportunities by inhibiting mitotic kinases Curr. Opin. Pharmacol. 8 2008 375 383
152. P.A. Pérez-Mancera, C. Bermejo-Rodríguez, M. Sánchez-Martín, F. Abollo-Jiménez, B. Pintado, and I. Sánchez-García FUS-DDIT3 prevents the development of adipocytic precursors in liposarcoma by repressing PPARgamma and C/EBPalpha and activating eIF4E PLoS One 3 2008 e2569
153. G. Pérez-Tenorio, L. Alkhori, B. Olsson, M.A. Waltersson, B. Nordenskjöld, L.E. Rutqvist, L. Skoog, and O. Stl PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer Clin. Cancer Res. 13 2007 3577 3584 (Pubitemid 46955118)
154. N. Pervaiz, N. Colterjohn, F. Farrokhyar, R. Tozer, A. Figueredo, and M. Ghert A systematic metaanalysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma Cancer 113 2008 573 581
155. I.A. Petersen, M.G. Haddock, J.H. Donohue, D.M. Nagorney, J.P. Grill, D.J. Sargent, and L.L. Gunderson Use of intraoperative electron beam radiotherapy in the management of retroperitoneal soft tissue sarcomas Int. J. Radiat. Oncol. Biol. Phys. 52 2002 469 475 (Pubitemid 34170851)
156. H.M. Pinedo, C.P. Vendrik, V.H. Bramwell, E.A. van Slooten, D.P. Deakin, J.A. van Unnik, M. Staquet, R. Sylvester, and G. Bonadonna Evaluation of adjuvant therapy in soft tissue sarcoma. A collaborative multidisciplinary approach. E. O. R. T. C. protocol 62771 Eur. J. Cancer 15 1979 811 820 (Pubitemid 9198553)
157. M.J. Pishvaian, A.J. Cotarla, J.F. Wagner, A.R. Deeken, J.J. He, G.D. Hwang, A. Demetri, C. Halim, and J. Copigneaux Marshall Final reporting of a phase I clinical trial of the oral PPAR-gamma agonist CS-7017, in patients with advanced malignancies J. Clin. Oncol. 28 2010 15s
158. P.W. Pisters, L.B. Harrison, D.H. Leung, J.F. Woodruff, E.S. Casper, and M.F. Brennan Long-term results of a prospective randomized trial of adjuvant brachytherapy in soft tissue sarcoma J. Clin. Oncol. 14 1996 859 868 (Pubitemid 26085531)
159. G. Pitson, P. Robinson, D. Wilke, R.A. Kandel, L. White, A.M. Griffin, R.S. Bell, C.N. Catton, J.S. Wunder, and B. O'Sullivan Radiation response: an additional unique signature of myxoid liposarcoma Int. J. Radiat. Oncol. Biol. Phys. 60 2004 522 526 (Pubitemid 39233472)
160. S. Polager, and D. Ginsberg p53 and E2f: partners in life and death Nat. Rev. Cancer 9 2009 738 748
161. T.H. Rabbitts, A. Forster, R. Larson, and P. Nathan Fusion of the dominant negative transcription regulator CHOP with a novel gene FUS by translocation t(12;16) in malignant liposarcoma Nat. Genet. 4 1993 175 180 (Pubitemid 23179103)
162. J.M. Reichert, and V.E. Valge-Archer Development trends for monoclonal antibody cancer therapeutics Nat. Rev. Drug Discov. 6 2007 349 356 (Pubitemid 46696550)
163. G. Rena, S. Guo, S.C. Cichy, T.G. Unterman, and P. Cohen Phosphorylation of the transcription factor forkhead family member FKHR by protein kinase B J. Biol. Chem. 274 1999 17179 17183
164. S.A. Rosenberg, J. Tepper, E. Glatstein, J. Costa, A. Baker, M. Brennan, E.V. DeMoss, C. Seipp, W.F. Sindelar, P. Sugarbaker, and R. Wesley The treatment of softtissue sarcomas of the extremities: Prospective randomized evaluations of 1) limb-sparing surgery plus radiation therapy compared with amputation and 2) the role of adjuvant chemotherapy Ann. Surg. 196 1982 305 315 (Pubitemid 12052461)
165. E.D. Rosen, and O.A. MacDougald Adipocyte differentiation from the inside out Nat. Rev. Mol. Cell. Biol. 7 2006 885 896 (Pubitemid 44871415)
166. H.K. Roy, B.F. Olusola, D.L. Clemens, W.J. Karolski, A. Ratashak, H.T. Lynch, and T.C. Smyrk AKT proto-oncogene overexpression is an early event during sporadic colon carcinogenesis Carcinogenesis 23 2002 201 205 (Pubitemid 34213570)
167. B.P. Rubin, and C.D.M. Fletcher The cytologenetics of lipomatous tumours Histopathology 30 1997 507 511
168. M. Sabbah, S. Emami, G. Redeuilh, S. Julien, G. Prevost, and A. Zimber Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in eptithelial cancers Drug Resist. Updat. 11 2008 123 151
169. L.B. Saltz, N.J. Meropol, P.J. Loehrer Sr., M.N. Needle, J. Kopit, and R.J. Mayer Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor J. Clin. Oncol. 22 2004 1201 1208 (Pubitemid 41079832)
170. A.A. Sandberg Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors, Liposarcoma Cancer Genet. Cytogenet. 155 2004 1 24 (Pubitemid 39446608)
171. T. Santarius, J. Shipley, D. Brewer, M.R. Stratton, and C.S. Cooper A census of amplified and overexpressed human cancer genes Nat. Rev. Cancer 10 2010 59 64
172. S.W. Santoro, and G.F. Joyce A general purpose RNA-cleaving DNA enzyme Proc. Natl. Acad. Sci. U. S. A. 94 1997 4262 4266 (Pubitemid 27194229)
173. Sarcoma Meta-analysis Collaboration Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Sarcoma Metaanalysis Collaboration Lancet 350 1997 1647 1654
174. P. Sarraf, E. Mueller, D. Jones, F.J. King, D.J. DeAngelo, and J.B. Partridge Differentiation and reversal of malignant changes in colon cancer through PPARgamma Nat. Med. 4 1998 1046 1052 (Pubitemid 28417337)
175. M.G. Schlieman, B.N. Fahy, R. Ramsamooj, L. Beckett, and R.J. Bold Incidence, mechanism and prognostic value of activated AKT in pancreas cancer Br. J. Cancer 89 2003 2110 2115 (Pubitemid 38030911)
176. J.H. Schwab, P. Boland, T. Guo, M.F. Brennan, S. Singer, J.H. Healey, and C.R. Antonescu Skeletal metastases in myxoid liposarcoma: an unusual pattern of distant spread Ann. Surg. Oncol. 14 2007 1507 1514 (Pubitemid 46536828)
177. P. Sdek, H. Ying, D.L. Chang, W. Qiu, H. Zheng, R. Touitou, M.J. Allday, and Z.X. Xiao MDM2 promotes proteasome dependent ubiquitin-independent degradation of retinoblastoma protein Mol. Cell. 20 2005 699 708 (Pubitemid 41740692)
178. S. Sebastian, A. Azzariti, N. Silvestris, L. Porcelli, A. Russo, and A. Paradiso p53 as the main traffic controller of the cell signaling network Front Biosci. 15 2010 1172 1190
179. C. Sessa, A. Perotti, C. Noberasco, F. De Braud, E. Gallerani, S. Cresta, M. Zucchetti, L. Vigan, A. Locatelli, J. Jimeno, J.W. Feilchenfeldt, M. D'Incalci, G. Capri, N. Ielmini, and L. Gianni Phase I clinical and pharmacokinetic study of trabectedin and doxorubicin in advanced soft tissue sarcoma and breast cancer Eur. J. Cancer 45 2009 1153 1161
180. E. Shaulian, and M. Karin AP-1 as a regulator of cell life and death Nat. Cell Biol. 4 2002 E131 E136
181. L.K. Shawver, D. Slamon, and A. Ullrich Smart drugs: tyrosine kinase inhibitors in cancer therapy Cancer Cell 1 2002 117 123
182. C.J. Sherr, and J.M. Roberts Living with or without cyclins and cyclin-dependent kinases Genes Dev. 18 2004 2699 2711 (Pubitemid 39507762)
183. W.F. Sindelar, T.J. Kinsella, P.W. Chen, T.F. DeLaney, J.E. Tepper, S.A. Rosenberg, and E. Glatstein Intraoperative radiotherapy in retroperitoneal sarcomas: final results of a prospective, randomized, clinical trial Arch. Surg. 4 1993 402 410 (Pubitemid 23115380)
184. S. Singer, C.R. Antonescu, E. Riedel, and M.F. Brennan Histologic subtype and margin of resection predict pattern of recurrence and survival for retroperitoneal liposarcoma Ann. Surg. 238 2003 358 370
185. S. Singer, N.D. Socci, G. Ambrosini, E. Sambol, P. Decarolis, Y. Wu, R. O'Connor, R. Maki, A. Viale, C. Sander, G.K. Schwartz, and C.R. Antonescu Gene expression profiling of liposarcoma identifies distinct biological types/subtypes and potential therapeutic targets in well-differentiated and dedifferentiated liposarcoma Cancer Res. 67 2007 6626 6636 (Pubitemid 47105508)
186. S. Sleijfer, I. Ray-Coquard, Z. Papai, A. Le Cesne, M. Scurr, P. Schöffski, F. Collin, L. Pandite, S. Marreaud, A. De Brauwer, M. van Glabbeke, J. Verweij, and J.Y. Blay Pazopanib, a multikinase angiogenesis inhibitor in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043) J. Clin. Oncol. 27 2009 3126 3132
187. S. Sleijfer, M. Ouali, M. van Glabbeke, A. Krarup-Hansen, S. Rodenhuis, A. Le Cesne, P.C. Hogendoorn, J. Verweij, and J.Y. Blay Prognostic and predictive factors for outcome to first line Ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas. An exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG) Eur. J. Cancer 46 2010 72 83
188. T.A. Smith, K.A. Easley, and J.R. Goldblum Myxoid/round cell liposarcoma of the extremities. A clinicopathologic study of 29 cases with particular attention to extent of round cell liposarcoma Am. J. Surg. Pathol. 20 1996 171 180 (Pubitemid 26038993)
189. E.L. Snyder, D.J. Sandstrom, K. Law, C. Fiore, E. Sicinska, J. Brito, D. Bailey, J.A. Fletcher, M. Loda, S.J. Rodig, P. Dal Cin, and C.D. Fletcher c-Jun amplification and overexpression are oncogenic in liposarcoma but not always sufficient to inhibit the adipocytic differentiation programme J. Pathol. 218 2009 292 300
190. S.P. Staal Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma Proc. Natl. Acad. Sci. U. S. A. 84 1987 5034 5037 (Pubitemid 17095859)
191. P.D. Stefanovski, E. Bidoli, A. De Paoli, A. Buonadonna, G. Boz, M. Libra, S. Morassut, C. Rossi, A. Carbone, and S. Frustaci Prognostic factors in soft tissue sarcomas: A study of 395 patients Eur. J. Surg. Oncol. 8 2002 153 164 (Pubitemid 35023657)
192. A. Stojadinovic, D.H. Leung, A. Hoos, D.P. Jaques, J.J. Lewis, and M.F. Brennan Analysis of the prognostic significance of microscopic margins in 2,084 localized primary adult soft tissue sarcomas Ann. Surg. 235 2002 424 434 (Pubitemid 34183894)
193. L. Svancárová, J.Y. Blay, I.R. Judson, Q.G. van Hoesel, and A.T. van Oosterom Gemcitabine in advanced adult soft-tissue sarcomas: A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group Eur. J. Cancer. 38 2002 556 559 (Pubitemid 34185396)
194. Y. Tao, J. Bourhis, and E. Deutsch Mechanisms of disease: signaling of the insulin-like growth factor 1 receptor pathway - therapeutic perspectives in cancer Nat. Clin. Pract. Oncol. 4 2007 591 602 (Pubitemid 47534758)
195. B.S. Taylor, J. Barretina, N.D. Socci, P. Decarolis, M. Ladanyi, M. Meyerson, S. Singer, and C. Sander Functional copy-number alterations in cancer PLoS One 3 2008 e3179
196. S. Thelin-Järnum, C. Lassen, I. Panagopoulos, N. Mandahl, and P. Aman Identification of genes differentially expressed in TLS-CHOP carrying myxoid liposarcomas Int. J. Cancer 83 1999 30 33 (Pubitemid 29409472)
197. Tontonoz, P., Hu, E., Spiegelman, B.M., 1995 Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell 79, 1147-1156.
198. P. Tontonoz, S. Singer, B.M. Forman, P. Sarraf, J.A. Fletcher, and C.D. Fletcher Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor Proc. Natl. Acad. Sci. U. S. A. 94 1997 237 241 (Pubitemid 27027193)
199. L.C. Trotman, A. Alimonti, P.P. Scaglioni, J.A. Koutcher, C. Cordon-Cardo, and P.P. Pandolfi Identification of a tumour suppressor network opposing nuclear Akt function Nature 441 2006 523 527 (Pubitemid 44050155)
200. J. Tsurutani, J. Fukuoka, H. Tsurutani, J.H. Shih, S.M. Hewitt, W.D. Travis, J. Jen, and P.A. Dennis Evaluation of two phosphorylation sites improves the prognostic significance of Akt activation in non-small-cell lung cancer tumors J. Clin. Oncol. 24 2006 306 314 (Pubitemid 46622059)
201. A. Ullrich, and J. Schlessinger Signal transduction by receptors with tyrosine kinase activity Cell 61 1990 203 212
202. Vassilev, L.T., Vu, B.T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., Fotouhi, N., Liu, E.A., 2004. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303, 844-848. (Pubitemid 38174664)
203. J. Verweij, G. Catimel, A. Sulkes, C. Sternberg, I. Wolff, S. Aamdal, and Q. van Hoesel Phase II studies of docetaxel in the treatment of various solid tumours: EORTC Early Clinical Trials Group and the EORTC Soft Tissue and Bone Sarcoma Group Eur. J. Cancer 31A 1995 S21 S24
204. Z. Wang, Y. Li, A. Ahmad, A.S. Azmi, D. Kong, S. Banerjee, and F.H. Sarkar Targeting miRNAs involved in cancer stem cells and EMT regulation: An emerging concept in overcoming drug resistance Drug Resist. Updat. 13 2010 109 118
205. J. Weaver, E. Downs-Kelly, J.R. Goldblum, S. Turner, S. Kulkarni, R.R. Tubbs, B.P. Rubin, and M. Skacel Fluorescence in situ hybridization for MDM2 gene amplification as a diagnostic tool in lipomatous neoplasms Mod. Pathol. 21 2008 943 949
206. R.A. Weinberg The retinoblastoma protein and cell cycle control Cell 81 1995 323 330
207. S.W. Weiss, and V.K. Rao Well-differentiated liposarcoma (atypical lipoma) of deep soft tissue of the extremities, retroperitoneum, and miscellaneous sites. A follow-up study of 92 cases with analysis of the incidence of "dedifferentiation" Am. J. Surg. Pathol. 16 1992 1051 1058
208. S.W. Weiss, and J.R. Goldblum S.W. Weiss, J.R. Goldblum, Enzinger and Weiss's soft tissue tumors fifth ed. 2008 Mosby-Elsevier Philadelphia
209. P.J. Woll, M. van Glabbeke, P. Hohenberger, and A. Le Cesne EORTC Soft Tissue & Bone Sarcoma Group: Adjuvant chemotherapy (CT) with doxorubicin and ifosfamide in resected soft tissue sarcoma (STS): Interim analysis of a randomised phase III trial J. Clin. Oncol. 25 2007 10008 (ASCO Meeting Abstracts)
210. Z.X. Xiao, J. Chen, A.J. Levine, N. Modjtahedi, J. Xing, W.R. Sellers, and D.M. Livingston Interaction between the retinoblastoma protein andthe oncoprotein MDM2 Nature 375 1995 694 698
211. J.C. Yang, A.E. Chang, A.R. Baker, W.F. Sindelar, D.N. Danforth, S.L. Topalian, T. DeLaney, E. Glatstein, S.M. Steinberg, M.J. Merino, and S.A. Rosenberg Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity J. Clin. Oncol. 16 1998 197 203 (Pubitemid 28041599)
212. J.C. Yang, L. Haworth, R.M. Sherry, P. Hwu, D.J. Schwartzentruber, S.L. Topalian, S.M. Steinberg, H.X. Chen, and S.A. Rosenberg A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer New Engl. J. Med. 349 2003 427 434 (Pubitemid 36910021)
213. G.K. Zagars, M.S. Goswitz, and A. Pollack Liposarcoma: outcome and prognostic factors following conservation surgery and radiation therapy Int. J. Radiat. Oncol. Biol. Phys. 36 1996 311 319 (Pubitemid 26359454)
214. G.K. Zagars, M.T. Ballo, P.W. Pisters, R.E. Pollock, S.R. Patel, and R.S. Benjamin Surgical margins and reresection in the management of patients with soft tissue sarcoma using conservative surgery and radiation therapy Cancer 97 2003 2544 2553 (Pubitemid 36542494)
215. M. Zhan, D. Yu, A. Lang, L. Li, and R.E. Pollock Wild type p53 sensitizes soft tissue sarcoma cells to doxorubicin by down-regulating multidrug resistance-1 expression Cancer 92 2001 1556 1566 (Pubitemid 32947842)
216. G.Y. Zhang, N. Ahmed, C. Riley, K. Oliva, G. Barker, M.A. Quinn, and G.E. Rice Enhanced expression of peroxisome proliferator-activated receptor gamma in epithelial ovarian carcinoma Br. J. Cancer 92 2005 113 119 (Pubitemid 40188443)
217. B.P. Zhou, Y. Liao, W. Xia, B. Spohn, M.H. Lee, and M.C. Hung Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu overexpressing cells Nat. Cell Biol. 3 2001 245 252 (Pubitemid 32201319)
218. Q.S. Zhu, W. Ren, B. Korchin, G. Lahat, A. Dicker, Y. Lu, G. Mills, R.E. Pollock, and D. Lev Soft tissue sarcoma cells are highly sensitive to AKT blockade: a role for p53-independent up-regulation of GADD45 alpha Cancer Res. 68 2008 2895 2903 (Pubitemid 351556289)
219. S. Zimmermann, and K. Moelling Phosphorylation and regulation of Raf by Akt (protein kinase B) Science 286 1999 1741 1744 (Pubitemid 129515882)
220. R.A. Zlotecki, T.S. Katz, C.G. Morris, D.S. Lind, and S.N. Hochwald Adjuvant radiation therapy for resectable retroperitoneal soft tissue sarcoma: The University of Florida experience Am. J. Clin. Oncol. 28 2005 310 316 (Pubitemid 40800485)